Dual CD19/CD20 cell therapy for relapsed or refractory B‑cell non‑Hodgkin lymphoma

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This open‑label, early phase 1 dose‑escalation and dose‑extension trial gives eligible adults a single infusion of LUCAR‑E9D or LUCAR‑E9K after lymphodepleting chemotherapy and follows them for safety and response. The main goals are to define tolerability, identify a recommended dose, and collect preliminary evidence of anti‑tumor activity. Participants must have relapsed or refractory B‑cell non‑Hodgkin lymphoma expressing CD19 and/or CD20 and meet performance and laboratory eligibility. The protocol includes screening, pre‑treatment lymphodepletion, the cell infusion, and scheduled follow‑up visits to monitor adverse events and disease status.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Subjects have fully understood the possible risks and benefits of participating in this study, are willing to follow and able to complete all trial procedures and have signed informed consent.
2. Aged 18-75 years (inclusive).
3. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
4. Histologically confirmed B-cell non-Hodgkin Lymphoma that expresses at least one of CD19/CD20.
5. At least one evaluable tumor lesion according to Lugano 2014 criteria.
6. Response to prior therapy is consistent with one of the following:

1） Patients with B-NHL who are primary refractory and are unsuitable or unwilling to receive autologous CAR-T cell therapy; 2） primary refractory is defined as the best response to first-line treatment being SD or PD; 3） Relapse within 12 months after achieving CR with first-line chemotherapy and immunotherapy; 7. Life expectancy≥ 3 months 8. Women of childbearing potential must have a negative highly sensitive serum pregnancy test (β-human chorionic gonadotropin \[β-hCG\]) at screening and before the first administration of cyclophosphamide and fludarabine treatment;

Exclusion Criteria:

1. Diagnosed with or treated for other invasive malignancies besides B-cell non-Hodgkin lymphoma.
2. Active acute or chronic graft-versus-host disease (GVHD), except for grade 1 skin involvement; or requiring immunosuppressive treatment for GVHD within 4 weeks prior to enrollment;
3. Active CNS involvement (symptomatic or positive cerebrospinal fluid or imaging data), prior CNS infiltration but currently in remission (asymptomatic and negative cerebrospinal fluid and/or imaging data) is eligible;
4. Significant bleeding tendency, such as gastrointestinal bleeding, hemorrhagic cystitis, coagulopathy.
5. Chronic diseases treated with steroids or other immunosuppressants. The following situations are excluded: use of topical, ocular, intra-articular, intranasal, and inhaled corticosteroids; short-term use of corticosteroids for prophylaxis;
6. Severe underlying diseases, such as: - Evidence of severe active viral, bacterial infections, or uncontrolled systemic fungal infections; - Active or unstable autoimmune diseases, or autoimmune diseases within the past 3 years with potential for relapse;
7. Breastfeeding women;

Where it's running

• The First Affiliated Hospital of USTC (Anhui Provincial Hospital)
  Hefei, China Recruiting
• The Second Affiliated Hospital of Xi'an Jiaotong University
  Xi'an, China Recruiting
• Affiliated Hospital of Xuzhou Medical University
  Xuzhou, China Recruiting

Study contacts

• Study coordinator: Kai Hu
• Email: huk@gobroadhealthcare.com
• Phone: +86 15010390336

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• XH001 with neoantigen vaccine–primed tumor-specific T cells for advanced gastrointestinal cancer

  This trial tests whether combining XH001 injections with T cells activated by a tumor neoantigen vaccine is safe and can shrink tumors or extend life in adults with advanced gastrointestinal cancer.

  Recruiting Phase 1 Beijing GoBroad Hospital · Beijing · NCT07329894

• TC-G203 treatment for GPC3-positive advanced solid tumors

  This trial will test a single-dose TC-G203 cell therapy to see if it is safe and helps adults with GPC3-positive recurrent or metastatic solid tumors who have already tried other treatments.

  Recruiting Early Phase 1 Beijing GoBroad Hospital · Beijing, Beijing Municipality and 1 other locations · NCT07242417

• CT041 after first-line treatment for CLDN18.2-positive advanced gastric or gastroesophageal junction cancer

  This study will test CT041, an autologous CLDN18.2-targeted CAR T-cell treatment, for people with advanced gastric or gastroesophageal junction adenocarcinoma after completing first-line therapy.

  Recruiting Beijing GoBroad Hospital · Beijing · NCT07179484

• OL-CD19-GDT CAR‑T for relapsed or refractory systemic sclerosis and primary Sjögren's syndrome

  This trial will try the CAR‑T therapy OL‑CD19‑GDT in adults whose systemic sclerosis or primary Sjögren's syndrome has relapsed or not responded to other treatments to see if it is safe and helps.

  Recruiting Phase 1 Beijing GoBroad Hospital · Beijing · NCT07167537

• Safety testing of STR-P004 in adults with relapsed or refractory autoimmune diseases

  This study will try multiple doses of STR-P004 to see if it's safe, tolerated, and how it behaves in adults whose autoimmune disease has relapsed or not responded to treatment.

  Recruiting Beijing GoBroad Hospital · Beijing · NCT07143617

• Nanobody CD5 CAR‑T for relapsed or refractory CD5‑positive T‑cell cancers

  This will test a CD5-targeted CAR‑T cell treatment using patients' own or donor-derived cells to try to help people with relapsed or refractory CD5+ T‑cell leukemias and lymphomas.

  Recruiting at 3 sites Phase 1/2 Beijing GoBroad Hospital · Beijing, Beijing Municipality and 3 other locations · NCT07070323

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.